AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29771062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal irrigation with saline
Number of subjects: 75
Study 29771062 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray
Number of subjects: 75
Study 29771062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal irrigation with saline and budesonide
Number of subjects: 75
Study 29771062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray with 2.3% hypertonic saline
Number of subjects: 75
Study 24615948 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolift Total
Number of subjects: 70
Study 24615948 — intervention group
Group type: COMPARATOR
Intervention: Sacrospinous fixation (SSF)
Number of subjects: 70
Study 21844879 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 564
Study 21844879 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 2.4/3.0 mg (pooled group)
Number of subjects: 564
Study 21844879 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 2.4/3.0 mg (completers)
Number of subjects: 564
Study 21844879 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 2.4/3.0 mg
Number of subjects: 564
Study 21844879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study 21844879 — intervention group
Group type: COMPARATOR
Intervention: Orlistat 120 mg × 3
Number of subjects: 564
Study 19106739 — intervention group
Group type: EXPERIMENTAL
Intervention: theory‐based smoking reduction intervention that combined telephone counseling and tailored newsletters
Number of subjects: 320
Study 19106739 — intervention group
Group type: COMPARATOR
Intervention: enhanced usual care
Number of subjects: 320
Study 17484348 — intervention group
Group type: EXPERIMENTAL
Intervention: 80‐mg atorvastatin for 4 days
Number of subjects: 16
Study 17484348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15115251 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisone-acetate (12.5 mg at 16.00 h and 25 mg at 07.00 h)
Number of subjects: 11
Study 15115251 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (N=8)
Number of subjects: 11
Study 11135718 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow sevoflurane plus probenecid (LSP)
Number of subjects: 64
Study 11135718 — intervention group
Group type: COMPARATOR
Intervention: Low-flow sevoflurane (LS)
Number of subjects: 64
Study 11135718 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow sevoflurane plus probenecid (HSP)
Number of subjects: 64
Study 11135718 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow sevoflurane (HS)
Number of subjects: 64
Study 9576423 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/d)
Number of subjects: 0
Study 9576423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7881705 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevantolol
Number of subjects: 0
Study 7881705 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 2908300 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25mg twice daily
Number of subjects: 49
Study 2908300 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 50mg twice daily
Number of subjects: 49
Study 31821014 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based intervention
Number of subjects: 112
Study 29553901 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh-frozen canine cadavers (FFCCs)
Number of subjects: 48
Study 29553901 — intervention group
Group type: COMPARATOR
Intervention: Canine simulator
Number of subjects: 48
Study 27117690 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral laser microsurgery (TLM)
Number of subjects: 56
Study 27117690 — intervention group
Group type: COMPARATOR
Intervention: Vertical hemilaryngectomy
Number of subjects: 56
Study 25280934 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Number of subjects: 129
Study 25280934 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg
Number of subjects: 129
Study 25280934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 24360050 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex) 0.3 µg/kg intravenously for initial bolus (duration 15 min) and then 0.3 µg·kg(‐1)·h(‐1) continuous infusion
Number of subjects: 60
Study 24360050 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex) 0.5 µg/kg intravenously (duration 15 min) for initial load and then 0.3 µg·kg(‐1)·h(‐1) continuous infusion
Number of subjects: 60
Study 24360050 — intervention group
Group type: COMPARATOR
Intervention: No sedative anesthetic
Number of subjects: 60
Study 20728808 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids rescue courses (betamethasone)
Number of subjects: 0
Study 20728808 — intervention group
Group type: COMPARATOR
Intervention: Multiple courses of antenatal corticosteroids
Number of subjects: 0
Study 18461376 — intervention group
Group type: EXPERIMENTAL
Intervention: Active suction device (S)
Number of subjects: 0
Study 18461376 — intervention group
Group type: COMPARATOR
Intervention: Control, nonsuction device (NS)
Number of subjects: 0
Study 17131979 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirituality group (8-week audiotaped spirituality home-study program)
Number of subjects: 165
Study 17131979 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation group (attendance at facilitated classes for 8 weeks)
Number of subjects: 165
Study 17131979 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no intervention for 12 weeks)
Number of subjects: 165
Study 17131979 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirituality group
Number of subjects: 165
Study 17131979 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation group
Number of subjects: 165
Study 17131979 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 165
Study 14656280 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin (90 mg/m2 every 3 weeks)
Number of subjects: 153
Study 14656280 — intervention group
Group type: COMPARATOR
Intervention: Observation (no further treatment)
Number of subjects: 153
Study 10962520 — intervention group
Group type: EXPERIMENTAL
Intervention: Valyl-Tyrosine (VY) 3 mg in a 100-ml drink administered twice a day for 4 weeks
Number of subjects: 29
Study 10962520 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (100-ml)
Number of subjects: 29
Study 10962520 — intervention group
Group type: EXPERIMENTAL
Intervention: Valyl-Tyrosine (VY)
Number of subjects: 29
Study 8783393 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg triazolam (TRZ)
Number of subjects: 10
Study 8783393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7880476 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma 3 Primer
Number of subjects: 34
Study 7880476 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma 2000 Conditioner
Number of subjects: 34
Study 7880476 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study 3510286 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (50 mg IV bolus on admission, then 100 mg on Days 1, 2, and 3, 50 mg on Day 4, and 25 mg on Day 5 on continuous IV infusion)
Number of subjects: 0
Study 3510286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30352997 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (n = 26)
Number of subjects: 51
Study 27066739 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS withdrawal group
Number of subjects: 2296
Study 27066739 — intervention group
Group type: COMPARATOR
Intervention: ICS continuation group
Number of subjects: 2296
Study 25569441 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk quartiles 1 to 4 (1: 9%, 2: 18%, 3: 25%, 4: 48%)
Number of subjects: 17012
Study 25569441 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk quartiles
Number of subjects: 17012
Study 23183261 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS at 2 pps
Number of subjects: 30
Study 23183261 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS at 30 pps
Number of subjects: 30
Study 23183261 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS at 80 pps
Number of subjects: 30
Study 23183261 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS at lower back
Number of subjects: 30
Study 23183261 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS at tibia and forearm
Number of subjects: 30
Study 22041002 — intervention group
Group type: EXPERIMENTAL
Intervention: Child him/herself in front of the mirror
Number of subjects: 141
Study 22041002 — intervention group
Group type: EXPERIMENTAL
Intervention: Another person with the child in the mirror
Number of subjects: 141
Study 22041002 — intervention group
Group type: COMPARATOR
Intervention: Giant TBM
Number of subjects: 141
Study 22041002 — intervention group
Group type: COMPARATOR
Intervention: Animal TBM puppet
Number of subjects: 141
Study 18257133 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of risperidone tablets
Number of subjects: 18
Study 18257133 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of risperidone tablets
Number of subjects: 18
Study 16204301 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA microemulsion (CsA‐ME)
Number of subjects: 98
Study 12657097 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide
Number of subjects: 37
Study 12657097 — intervention group
Group type: COMPARATOR
Intervention: LHRH agonist
Number of subjects: 37
Study 10723579 — intervention group
Group type: EXPERIMENTAL
Intervention: lenograstim at 8 micrograms/kg/day
Number of subjects: 36
Study 10723579 — intervention group
Group type: EXPERIMENTAL
Intervention: lenograstim at 11 micrograms/kg/day
Number of subjects: 36
Study 10723579 — intervention group
Group type: EXPERIMENTAL
Intervention: lenograstim at 15 micrograms/kg/day
Number of subjects: 36
Study 8991589 — intervention group
Group type: COMPARATOR
Intervention: Estrogen therapy alone
Number of subjects: 351
Study 8991589 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy with nomegestrol acetate
Number of subjects: 351
Study 1541084 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted femoral arteriography
Number of subjects: 114
Study 1541084 — intervention group
Group type: COMPARATOR
Intervention: Physiological tests
Number of subjects: 114
Study 1541084 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (ankle-arm ratio)
Number of subjects: 114
Study 3886943 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive hospice care
Number of subjects: 100
Study 3886943 — intervention group
Group type: COMPARATOR
Intervention: Traditional medical care
Number of subjects: 100
Study 30859380 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI) with manual thrombus aspiration
Number of subjects: 144
Study 30859380 — intervention group
Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (PCI) without manual thrombus aspiration (control)
Number of subjects: 144
Study 30859380 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PCI with and without thrombus aspiration)
Number of subjects: 144
Study 29534736 — intervention group
Group type: COMPARATOR
Intervention: Sipuleucel-T alone
Number of subjects: 18
Study 29534736 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T followed by pTVG-HP DNA vaccine
Number of subjects: 18
Study 29534736 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study 26882043 — intervention group
Group type: EXPERIMENTAL
Intervention: VTP-27999 (75-600 mg)
Number of subjects: 22
Study 26882043 — intervention group
Group type: COMPARATOR
Intervention: Aliskiren (300 mg)
Number of subjects: 22
Study 26882043 — intervention group
Group type: EXPERIMENTAL
Intervention: VTP-27999 (150 mg)
Number of subjects: 22
Study 25141850 — intervention group
Group type: EXPERIMENTAL
Intervention: iStoppFalls system exercise program (16-week duration, 180 minutes/week)
Number of subjects: 160
Study 25141850 — intervention group
Group type: EXPERIMENTAL
Intervention: iStoppFalls system exercise program
Number of subjects: 160
Study 22313154 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg once daily for 24 weeks
Number of subjects: 455
Study 22313154 — intervention group
Group type: COMPARATOR
Intervention: placebo once daily for 24 weeks
Number of subjects: 455
Study 20729527 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol cues
Number of subjects: 10
Study 20729527 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydrug cues
Number of subjects: 10
Study 20729527 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana cues
Number of subjects: 10
Study 17563091 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of long-acting benzodiazepines
Number of subjects: 18490
Study 17563091 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of long-acting benzodiazepines (restricted to subjects with four or less prescriptions filled in the previous year)
Number of subjects: 18490
Study 17563091 — intervention group
Group type: COMPARATOR
Intervention: Case-crossover approach (all cases)
Number of subjects: 18490
Study 16154346 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of ephedrine 30 mg in 1 L of 0.9% saline after spinal block, titrated to maternal systolic pressure.
Number of subjects: 60
Study 16154346 — intervention group
Group type: COMPARATOR
Intervention: 1 L 0.9% saline before spinal block (control group).
Number of subjects: 60
Study 12012141 — intervention group
Group type: COMPARATOR
Intervention: Topotecan alone (1.5 mg/m² for 5 days)
Number of subjects: 10
Study 12012141 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan with amifostine (300 mg/m² prior to topotecan)
Number of subjects: 10
Study 12012141 — intervention group
Group type: COMPARATOR
Intervention: Topotecan alone
Number of subjects: 10
Study 12012141 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan with amifostine
Number of subjects: 10
Study 12012141 — intervention group
Group type: COMPARATOR
Intervention: Topotecan only
Number of subjects: 10
Study 10604482 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 37
Study 10604482 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 37
Study 10604482 — intervention group
Group type: COMPARATOR
Intervention: Normotensive controls
Number of subjects: 37
Study 10604482 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril and Losartan
Number of subjects: 37
Study 7782137 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ml 20% mannitol infusion and 10.0 g ascorbic acid infusion
Number of subjects: 42
Study 7782137 — intervention group
Group type: COMPARATOR
Intervention: Standard fibrinolytic therapy (control group)
Number of subjects: 42
Study 1486827 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg Zopiclone
Number of subjects: 10
Study 1486827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6371412 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy using electrocautery for dissection and hemostasis
Number of subjects: 0
Study 6371412 — intervention group
Group type: COMPARATOR
Intervention: Tonsillectomy performed by scissor dissection with suture hemostasis
Number of subjects: 0
Study 30770192 — intervention group
Group type: COMPARATOR
Intervention: Condition 1 (sitting for 7h interrupted by 3min light-intensity walking breaks every 60min)
Number of subjects: 12
Study 30770192 — intervention group
Group type: COMPARATOR
Intervention: Condition 2 (sitting for 7h interrupted by 3min light-intensity walking breaks every 30min)
Number of subjects: 12
Study 30770192 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 3 (sitting for 7h interrupted by 3min light-intensity walking breaks every 15min)
Number of subjects: 12
Study 30410129 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Number of subjects: 75
Study 30410129 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping
Number of subjects: 75
Study 27245918 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration on the less affected limb (LA)
Number of subjects: 16
Study 27245918 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration applied after FOG onset
Number of subjects: 16
Study 25304446 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality assessment and life events evaluation
Number of subjects: 252
Study 25304446 — intervention group
Group type: EXPERIMENTAL
Intervention: Social cognition tests
Number of subjects: 252
Study 25304446 — intervention group
Group type: EXPERIMENTAL
Intervention: Social cognition performance
Number of subjects: 252
Study 25304446 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain Magnetic Resonance Imaging
Number of subjects: 252
Study 22453200 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (300 mg daily at bedtime)
Number of subjects: 133
Study 22453200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 20525836 — intervention group
Group type: EXPERIMENTAL
Intervention: RANKL:OPG ratio and CTX‐I or CTX‐II
Number of subjects: 155
Study 20525836 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment at 3 months
Number of subjects: 155
Study 18027874 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg injection)
Number of subjects: 23
Study 18027874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 15608522 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 16
Study 12373046 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ST-T-changes
Number of subjects: 85
Study 12373046 — intervention group
Group type: COMPARATOR
Intervention: Patients without ECG alterations
Number of subjects: 85
Study 10418916 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-derived hepatitis B vaccine
Number of subjects: 649
Study 10418916 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 649
Study 8526975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.3 mg/kg
Number of subjects: 6
Study 8526975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Number of subjects: 6
Study 8526975 — intervention group
Group type: COMPARATOR
Intervention: Ketamine (various doses)
Number of subjects: 6
Study 2344010 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine treatment for four months
Number of subjects: 10
Study 7047536 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical resection of the lesion and the insertion of autologous bone grafts (Rad. series)
Number of subjects: 119
Study 7047536 — intervention group
Group type: COMPARATOR
Intervention: Debridement of the spinal focus without bone grafting (Deb. series)
Number of subjects: 119
Study 7047536 — intervention group
Group type: EXPERIMENTAL
Intervention: Rad. series
Number of subjects: 119
Study 7047536 — intervention group
Group type: COMPARATOR
Intervention: Deb. series
Number of subjects: 119
Study 31114950 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical guidance
Number of subjects: 60
Study 31114950 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical guidance
Number of subjects: 60
Study 31114950 — intervention group
Group type: COMPARATOR
Intervention: Blind insertion
Number of subjects: 60
Study 30849952 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 72
Study 30849952 — intervention group
Group type: COMPARATOR
Intervention: Standard Therapy (ST)
Number of subjects: 72
Study 30033111 — intervention group
Group type: COMPARATOR
Intervention: Limbal relaxing incisions (LRIs)
Number of subjects: 104
Study 30033111 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser arcuate keratotomy
Number of subjects: 104
Study 26984911 — intervention group
Group type: EXPERIMENTAL
Intervention: OP-1 combined with local bone
Number of subjects: 119
Study 26984911 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest autograft combined with local bone
Number of subjects: 119
Study 24009162 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered behavioral intervention
Number of subjects: 82
Study 21525141 — intervention group
Group type: EXPERIMENTAL
Intervention: Dioctahedral smectite (DS) 1.5 g thrice daily for 5 days
Number of subjects: 117
Study 21525141 — intervention group
Group type: EXPERIMENTAL
Intervention: Dioctahedral smectite (DS)
Number of subjects: 117
Study 19783713 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil 1000 mg with pantoprazole 40 mg twice daily
Number of subjects: 0
Study 19783713 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium with pantoprazole 40 mg twice daily
Number of subjects: 0
Study 17845320 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg b.i.d. for 48 h
Number of subjects: 104
Study 17845320 — intervention group
Group type: COMPARATOR
Intervention: Intravenous magnesium sulfate for maximum of 48 h
Number of subjects: 104
Study 17845320 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib and magnesium sulfate
Number of subjects: 104
Study 15237025 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 0
Study 15237025 — intervention group
Group type: COMPARATOR
Intervention: Conventional in vitro fertilization (IVF)
Number of subjects: 0
Study 12296413 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (Unison Laboratories, Thailand)
Number of subjects: 14
Study 12296413 — intervention group
Group type: COMPARATOR
Intervention: Reference product (Glaxo Wellcome, USA)
Number of subjects: 14
Study 9791049 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (0, 20 and 40 p.p.m.)
Number of subjects: 8
Study 9791049 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized prostaglandin I2 (10 microgram/ml)
Number of subjects: 8
Study 9791049 — intervention group
Group type: COMPARATOR
Intervention: Bicycle ergometry (positive control)
Number of subjects: 8
Study 7988077 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a) lipoprotein levels
Number of subjects: 0
Study 7988077 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA class II genotypes
Number of subjects: 0
Study 7988077 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative risk for CAD
Number of subjects: 0
Study 2563839 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 164